A Phase 1 interventional study of 0.1 mg/kg Dimethyltryptamine (DMT) and 0.3 mg/kg Dimethyltryptamine (DMT) in Major Depressive Disorder and Depression, sponsored by Yale University. Recruiting at 1 site in United States. Open to participants aged 21 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-18.
Sponsored by Yale University · Phase 1, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 22 studies in Depressive Disorder, Major by Yale University — 6 open to participants now, 8 under way, none of them phase 3. Depressive Disorder, Major · Yale University.
Among the 22 studies in Depressive Disorder, Major by Yale University, this one is the 14th largest by planned enrollment of the 16 interventional ones that give a count, is the only one that started in 2021, is one of 4 in phase 1, and was the 15th registered.
3,051 studies on the registry are indexed under Depressive Disorder, Major; 596 are open to participants now.
Browse Depressive Disorder, Major studies →6 of the 22 studies in Depressive Disorder, Major by Yale University are open now, in 1 country. Recruiting first, the newest first:
Yale University · Sites in United States
Ages 40–80 · Healthy volunteers
Yale University · Sites in United States
Yale University · Sites in United States
Ages 18–60
Yale University · Sites in United States
Ages 21–65
Yale University · Sites in United States
Ages 22+
By country, each count listing its studies:
Of the 419 Depressive Disorder, Major studies recruiting now, 93 (22%) set no upper age limit and 299 (71%) stop at 75 or younger; 55 take children under 18; 100 take healthy volunteers.
This study: 21 Years to 65 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
22 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 5 · Phase 3 1 · Phase 4 1
First in 2002; this study’s year is marked. 1 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 10 is below the median of 80 across 2,535 interventional studies indexed under Depressive Disorder, Major.
Median enrollment 29 across the 16 interventional studies, 65 across the 6 observational. Of the 13 that completed or were terminated, 6 (46%) have results posted.
This tab as a report to print or save as PDF → With an account.
Yale University is the lead sponsor of 1,773 studies on the registry; 298 are open to participants now.
Of its 221 completed or terminated interventional studies of FDA-regulated products, 129 (58%) have results posted.
2 of the studies in Depressive Disorder, Major by Yale University that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT02734602Yale UniversityImaging SV2A in Mood Disorders | 2027-01 |
| NCT07792252Yale UniversityREWIRE: Real-world Engagement With Interventional and Rejoyn Effectiveness | 2027-03 |
Add all 2 to your calendar (.ics) → With an account.
Among the 22 studies in Depressive Disorder, Major by Yale University, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this fixed order, open-label, dose-escalation study is to investigate the safety and efficacy of specific doses of dimethyltryptamine (DMT) in humans.
The results of this study will inform the doses to be used in a larger, double-blind, randomized, placebo-controlled, crossover study. Since the goal of the open label study is to inform the double-blind, randomized, placebo-controlled study, the investigators are citing the hypothesis of the latter solely for providing context. The investigators hypothesize that the administration of DMT will result in neuroplastic changes in healthy and depressed subjects. These changes in neuroplasticity will be indexed using electroencephalographic (EEG) measures and tasks. These neuronal changes may in parallel cause changes in mood measured both in healthy and depressed subjects, which will be captured using appropriate psychometric measures of mood.
Healthy controls inclusion criteria:
Healthy controls exclusion criteria:
Depression inclusion criteria:
Depression exclusion criteria:
-Unstable medical conditions
0.1 mg/kg DMT administered intravenously
Drug: 0.1 mg/kg Dimethyltryptamine (DMT)
0.3 mg/kg DMT administered intravenously
Drug: 0.3 mg/kg Dimethyltryptamine (DMT)
0.1 mg/kg DMT
Also known as: Low Dose DMT
0.3 mg/kg DMT
Also known as: Moderate Dose DMT
Change in Blood Pressure
Systolic and diastolic blood pressure will be measured before and several times after the administration of DMT on each test day.
Time frame: -60 and -30 minutes before DMT administration; 0, +5, +10, +15, +20, +30, +45, +60, and +120 minutes after DMT administration
Change in Heart Rate
Heart rate will be measured before and several times after the administration of DMT on each test day.
Time frame: -60 and -30 minutes before DMT administration; 0, +5, +10, +15, +20, +30, +45, +60, and +120 minutes after DMT administration
Change in Psychedelic Effects
The modified Altered States of Consciousness Rating Scale (ASC) will be used to assess drug-induced altered states of consciousness before and several times after drug administration. This is a 23-item subjective rating scale that will be completed using a visual analog scale format. Questions are scored 0 to 100 each; higher numbers indicate greater psychedelic effects.
Time frame: -60 minutes before DMT administration; 0, +30, and +60 minutes after DMT administration
Change in Anxiety
Anxiety will be assessed using a visual analog scale that subjects will be asked to score from 0 (not at all) to 100 (worst ever) to capture the net anxiety produced by DMT. This will be collected before and several times after DMT administration.
Time frame: -60 minutes before DMT administration; 0, +30, and +60 minutes after DMT administration
Drug Reinforcing Effects
Subjects will be asked to answer questions such as (1) How likely are you to use this drug? and (2) How much are you willing to pay for this experience? using a visual analog scale.
Time frame: +120 minutes after DMT administration
Overall Tolerability assessed by the VAS
Overall tolerability will be assessed using a visual analog scale that subjects will be asked to score from 0 (well tolerated) to 100 (intolerable) to capture the net tolerability of DMT.
Time frame: +120 minutes after DMT administration
Started Mar 2021 (actual). Primary completion is estimated for Jul 2030, 111 months after the start.
Of 49 non-industry phase 1 interventional studies under Depressive Disorder, Major, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 16. This study's planned 111 months is above that.
Counting every sponsor, half of 89 studies reached it within 16 months; a quarter within 5 and three quarters within 45.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 18, 2026: primary completion Jul 2026 → Jul 2030 and completion Dec 2026 → Dec 2030.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.